KR20090084335A - 혈관신생 억제용 약제학적 조성물 - Google Patents
혈관신생 억제용 약제학적 조성물 Download PDFInfo
- Publication number
- KR20090084335A KR20090084335A KR1020080010441A KR20080010441A KR20090084335A KR 20090084335 A KR20090084335 A KR 20090084335A KR 1020080010441 A KR1020080010441 A KR 1020080010441A KR 20080010441 A KR20080010441 A KR 20080010441A KR 20090084335 A KR20090084335 A KR 20090084335A
- Authority
- KR
- South Korea
- Prior art keywords
- hydrogen
- pharmaceutical composition
- alkyl
- hydroxy
- alkoxy
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Virology (AREA)
Abstract
Description
Claims (7)
- (a) 하기 화학식 1의 화합물의 약제학적 유효량; 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 혈관신생 억제용 조성물:화학식 1상기 화학식에서, R1-R12는 서로 독립적으로 수소, 할로, 히드록시, 시아노, 아미노, 니트로, 니트로소, 카르복실, C1-C12 알킬, C2-C6 알케닐기, C3-C8 사이클로알킬, C5-C7 사이클로알케닐, C1-C6 알킬아미노, C1-C6 알콕시, 아릴, 헤테로아릴, 아릴알킬, 아릴알케닐 또는 알킬아릴이고; R13은 수소, 히드록시, C1-C12 알킬 또는 C1-C6 알콕시이며; X는 산소 또는 황이다.
- 제 1 항에 있어서, 상기 R1은 수소, 히드록시, C1-C12 알킬 또는 C1-C6 알콕시인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 R2-R12는 서로 독립적으로 수소, 히드록시, C1-C12 알킬, 또는 C1-C6 알콕시인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 R13은 수소 또는 히드록시인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 X는 산소인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 R1은 히드록시이고, R2-R12는 수소이며, R13은 수소이고, X는 산소인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 약제학적 조성물은 암, 당뇨병성 망막증, 미숙아 망막증, 각막 이식 거부, 신생혈관 녹내장, 홍색증, 증식성 망막증, 건선, 혈우병성 관절, 아테롬성 동맥경화 플라크 내에서의 모세혈관 증식, 켈로이드, 상처 과립화, 혈관 접착, 류마티스 관절염, 골관절염, 자가면역 질환, 크론씨병, 재발협착증, 아테롬성 동맥경화, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 사구체신염, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관 이식 거부, 신사구체병증, 당뇨병, 염증 또는 신경퇴행성 질환의 비조절성 혈관신생-관련 질병 또는 질환의 예방 또는 치료에 이용되는 것을 특징으로 하는 약제학적 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080010441A KR100961891B1 (ko) | 2008-02-01 | 2008-02-01 | 혈관신생 억제용 약제학적 조성물 |
US12/865,356 US8450502B2 (en) | 2008-02-01 | 2009-01-30 | Pharmaceutical compositions for inhibiting angiogenesis |
CN2009800000051A CN101677990B (zh) | 2008-02-01 | 2009-01-30 | 用于抑制血管发生的药物组合物 |
JP2010500853A JP4991005B2 (ja) | 2008-02-01 | 2009-01-30 | 血管新生抑制用の薬剤学的組成物 |
PCT/KR2009/000457 WO2009107933A2 (en) | 2008-02-01 | 2009-01-30 | Pharmaceutical compositions for inhibiting angiogenesis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080010441A KR100961891B1 (ko) | 2008-02-01 | 2008-02-01 | 혈관신생 억제용 약제학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090084335A true KR20090084335A (ko) | 2009-08-05 |
KR100961891B1 KR100961891B1 (ko) | 2010-06-09 |
Family
ID=41016558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080010441A KR100961891B1 (ko) | 2008-02-01 | 2008-02-01 | 혈관신생 억제용 약제학적 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8450502B2 (ko) |
JP (1) | JP4991005B2 (ko) |
KR (1) | KR100961891B1 (ko) |
CN (1) | CN101677990B (ko) |
WO (1) | WO2009107933A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101298651B1 (ko) * | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230313199A1 (en) * | 2020-09-01 | 2023-10-05 | Massachusetts Institute Of Technology | Target for modulating body mass |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL99500A0 (en) | 1990-09-17 | 1992-08-18 | Agouron Pharma | Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same |
GB9225475D0 (en) * | 1992-12-05 | 1993-01-27 | Imp Cancer Res Tech | Compounds to combat angiogenesis |
JP2001518501A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | インデノ[1,2−c]−、ナフト[1,2−c]−およびベンゾ[6,7]シクロへプタ[1,2−c]ピラゾール誘導体 |
US20060070135A1 (en) | 1998-07-24 | 2006-03-30 | Michel Tremblay | Compositions and methods for inhibiting the enzymatic activity of PTP-1B |
US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
MXPA05009103A (es) * | 2003-02-28 | 2006-04-18 | Bayer Pharmaceuticals Corp | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. |
WO2009016081A2 (en) * | 2007-08-02 | 2009-02-05 | Actar Ab | Benzoind0l-2-one derivatives for use in therapy |
KR101229822B1 (ko) * | 2008-03-04 | 2013-02-05 | 연세대학교 산학협력단 | 혈관신생 억제용 약제학적 조성물 |
-
2008
- 2008-02-01 KR KR1020080010441A patent/KR100961891B1/ko active IP Right Grant
-
2009
- 2009-01-30 JP JP2010500853A patent/JP4991005B2/ja not_active Expired - Fee Related
- 2009-01-30 US US12/865,356 patent/US8450502B2/en active Active
- 2009-01-30 CN CN2009800000051A patent/CN101677990B/zh active Active
- 2009-01-30 WO PCT/KR2009/000457 patent/WO2009107933A2/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101298651B1 (ko) * | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2010522232A (ja) | 2010-07-01 |
CN101677990A (zh) | 2010-03-24 |
WO2009107933A2 (en) | 2009-09-03 |
JP4991005B2 (ja) | 2012-08-01 |
KR100961891B1 (ko) | 2010-06-09 |
US8450502B2 (en) | 2013-05-28 |
CN101677990B (zh) | 2012-09-26 |
WO2009107933A3 (en) | 2009-10-29 |
US20110039919A1 (en) | 2011-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160101162A (ko) | 코르티스타틴 유사체 및 그의 합성 및 용도 | |
JP2007084494A (ja) | Pim−1活性阻害剤 | |
US8884027B2 (en) | Melampomagnolide B derivatives as antileukemic and cytotoxic agents | |
WO2011069039A1 (en) | Hydrazone and diacyl hydrazine compounds and methods of use | |
Raghuvanshi et al. | Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: A mini-review | |
Zhang et al. | Antagonizing STAT3 activation with benzo [b] thiophene 1, 1-dioxide based small molecules | |
KR20180014832A (ko) | Nadph 옥시다제 4 억제제 | |
Antoszczak et al. | Synthesis and antiproliferative activity of new bioconjugates of Salinomycin with amino acid esters | |
CN101225070A (zh) | 用于抗肿瘤的药物 | |
EP2767538B1 (en) | Tetrandrine derivatives with substituted 5-carbon, preparation method and use thereof | |
NO342001B1 (no) | C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose. | |
KR100961891B1 (ko) | 혈관신생 억제용 약제학적 조성물 | |
KR101229822B1 (ko) | 혈관신생 억제용 약제학적 조성물 | |
KR20080081310A (ko) | 항암 효과가 높고 항말라리아 활성이 오래 지속되는트리옥산 이량체 | |
CA3190787A1 (en) | Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity | |
AU2004224488B2 (en) | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 | |
US9399644B2 (en) | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | |
MX2015000309A (es) | Terapia combinada para tratamiento de cancer e inmunosupresion. | |
JP2024508426A (ja) | 免疫調節物質及び免疫調節物質コンジュゲート | |
CN107629041B (zh) | 查尔酮类衍生物、其制备方法及其在医药上的应用 | |
CN111943947A (zh) | 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用 | |
JP6381605B2 (ja) | 脳卒中治療用のイリドイド配糖体類化合物、その医薬組成物及びその使用方法 | |
KR20110132056A (ko) | 피롤리딘 설포닐계 화합물을 포함하는 혈관신생 억제용 약제학적 조성물 | |
WO2014093652A1 (en) | Semi - synthetic mithramycin derivatives with anti-cancer activity | |
WO2020219819A1 (en) | Β−catenin/ b-cell lymphoma 9 protein−protein interaction inhibiting peptidomimetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130416 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140311 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150428 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160610 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170529 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180523 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190521 Year of fee payment: 10 |